How many more nails to seal the coffin of dose intensity? (Q73481573)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209658%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

0 references

1 reference

title

How many more nails to seal the coffin of dose intensity? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209658%20AND%20SRC:MED&resulttype=core&format=json

dose-response relationship

4 November 2019

main subject

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9209658

1 September 2024

author name string

W. P. McGuire

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9209658

1 September 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9209658

1 September 2024

publication date

1 April 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209658%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

4 November 2019

https://doi.org/10.1023/a:1008211203563

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9209658

https://api.elsevier.com/content/article/PII:S0923753419605326?httpAccept=text/xml

1 September 2024

1 reference

DOI

https://api.crossref.org/works/10.1023/A:1008211203563

https://api.elsevier.com/content/article/PII:S0923753419605326?httpAccept=text/plain

1 September 2024

1 reference

DOI

https://api.crossref.org/works/10.1023/A:1008211203563

http://academic.oup.com/annonc/article-pdf/8/4/311/19480747/8-4-311.pdf

1 September 2024

1 reference

https://api.crossref.org/works/10.1023/A:1008211203563

1 September 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209658%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209658%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209658%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

311-313

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209658%20AND%20SRC:MED&resulttype=core&format=json

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008211203563

7 January 2021

Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008211203563

7 January 2021

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008211203563

7 January 2021

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008211203563

7 January 2021

A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008211203563

7 January 2021

Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008211203563

7 January 2021

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008211203563

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008211203563

7 January 2021

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008211203563

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9209658%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference